Gastrointestinal Stromal Tumor (GIST) News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Blueprint Medicines Announces European Commission Approval of AYVAKYT(R) (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors
CAMBRIDGE, Mass., Sept. 25, 2020 -- (Healthcare Sales & Marketing Network) -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that ... Biopharmaceuticals, Regulatory Blueprint Medicines, AYVAKIT, avapritinib, gastrointestinal stromal tumor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 25, 2020 Category: Pharmaceuticals Source Type: news

Blueprint Medicines Strengthens Leadership with Appointment of Fouad Namouni, M.D., as President, Research and Development
Newly created role to oversee R&D organization and advance precision medicine portfolio vision CAMBRIDGE, Mass., Sept. 1, 2020 -- (Healthcare Sales & Marketing Network) -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company foc... Biopharmaceuticals, Personnel Blueprint Medicines, AYVAKIT, avapritinib, gastrointestinal stromal tumor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 1, 2020 Category: Pharmaceuticals Source Type: news

Ripretinib Extends Survival When All Else Fails in Advanced GIST Ripretinib Extends Survival When All Else Fails in Advanced GIST
Treatment with oral ripretinib significantly prolonged survival in patients with advanced gastrointestinal stromal tumors (GIST) who did not respond or were intolerant to three other tyrosine-kinase inhibitors in the INVICTUS study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 6, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Three Years of Imatinib May Halve Death Rate in GIST Three Years of Imatinib May Halve Death Rate in GIST
Giving patients with high-risk gastrointestinal stromal tumors imatinib for 3 years rather than 1 year may reduce 10-year mortality by half, say German and Finnish investigators.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 8, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

QINLOCK (Ripretinib), FDA Approved for Treatment of Gastrointestinal Stromal Tumors (GIST), Available at Biologics by McKesson
CARY, N.C., June 4, 2020 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Deciphera Pharmaceuticals as a specialty pharmacy provider for QINLOCKTM (ripretinib) for the treatment of adult patients with advanced gastrointestinal ... (Source: McKesson News)
Source: McKesson News - June 4, 2020 Category: Information Technology Source Type: news

Qinlock (Ripretinib) Approved as Fourth-Line Treatment for GIST
MONDAY, May 18, 2020 -- The U.S. Food and Drug Administration approved Qinlock (ripretinib) tablets as a fourth-line treatment for adults with advanced gastrointestinal stromal tumors (GISTs), the agency announced Friday. The approval follows four... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 18, 2020 Category: General Medicine Source Type: news

FDA Approves Ripretinib for Advanced GISTs FDA Approves Ripretinib for Advanced GISTs
The oral therapy is the first-ever drug specifically approved as a fourth-line treatment for advanced gastrointestinal stromal tumors (GISTs).FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - May 18, 2020 Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news

FDA approves ripretinib for advanced gastrointestinal stromal tumor
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 15, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors
FDA has approved Qinlock (ripretinib) tablets as the first new drug specifically approved as a fourth-line treatment for advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 15, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Blueprint Medicines Receives Complete Response Letter from FDA for Avapritinib New Drug Application for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
CAMBRIDGE, Mass., May 15, 2020 -- (Healthcare Sales & Marketing Network) -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that th... Biopharmaceuticals, FDA Blueprint Medicines, AYVAKIT, avapritinib, gastrointestinal stromal tumor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 15, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves Ripretinib Tablets for Advanced Gastrointestinal Stromal Tumor
Ripretinib is now indicated for adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with 3 or more kinase inhibitor therapies. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Approves Qinlock (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
WALTHAM, Mass.--(BUSINESS WIRE)--May 15, 2020-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the U.S. Food and Drug Administration (FDA) has approved Qinlock™ (ripretinib) for the treatment of adult patients with advanced... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 15, 2020 Category: Drugs & Pharmacology Source Type: news

Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor
VOYAGER did not meet the primary endpoint of an improvement in progression-free survival for avapritinib versus regorafenib in patients with third- or fourth-line GIST Plan to continue to prioritize portfolio opportunities in systemic mastocytosis and R... Biopharmaceuticals, Oncology Blueprint Medicines, avapritinib, gastrointestinal stromal tumor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 28, 2020 Category: Pharmaceuticals Source Type: news

FDA Grants Priority Review to Ripretinib for Advanced Gastrointestinal Stromal Tumors
The FDA granted a priority review to Deciphera Pharmaceuticals ’ new drug application for ripretinib to treat patients with advanced gastrointestinal stromal tumors. (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Deciphera Pharmaceuticals Announces U.S. Food And Drug Administration Acceptance Of New Drug Application And Priority Review For Ripretinib In Patients With Advanced Gastrointestinal Stromal Tumors
WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 12, 2020-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA)... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 12, 2020 Category: Drugs & Pharmacology Source Type: news